Lesional magnetization transfer ratio: a feasible outcome for remyelinating treatment trials in multiple sclerosis

Abstract

Magnetization transfer ratio (MTR) is a sensitive parameter to quantify the integrity of myelinated white matter in patients with multiple sclerosis. Lesional MTR decreases in the acute phase due to demyelination, and subsequently shows recovery depending on the degree of remyelination in the absence of axonal loss. Recovery of average lesion MTR therefore might prove a viable outcome measure to assess the effect of remyelinating agents. Our objective was to determine the required sample size for phase II multicentre clinical trials using the recovery of average lesion MTR as primary outcome measure. With 7-monthly MRI scans, the MTR evolution of 349 new enhancing lesions before and after enhancement was assessed in 32 MS patients from 5 centres. Multilevel models were fitted to the data yielding estimates for the variance components, which were applied in power calculations. Sample sizes were determined for placebo-controlled, multicentre trials using lesional MTR recovery post-enhancement as primary outcome measure. Average lesion MTR decreased slightly in the build-up to enhancement, decreased dramatically during enhancement and showed recovery in the period after cessation. The power calculations showed that for a power of 80%, approximately 136 patients per trial (mean number of 6 lesions per patient) are required to detect a 30% increase in lesional MTR post-enhancement compared with placebo, whereas 48 subjects are required to detect a 50% increase in lesional MTR compared with placebo. Recovery of lesion MTR is a feasible outcome measure for future multicentre clinical trials measuring the effect of remyelinating agents.

Keywords

magnetic resonance imaging magnetization transfer ratio multiple sclerosis sample size

Get full access to this article

View all access options for this article.

References

Brück W. , Bitsch A. , Kolenda H. , Brück Y. , Stiefel M. , Lassmann H. Inflammatory central nervous system demyelination: correlation of magnetic resonance imaging findings with lesion pathology. Ann Neurol 1997; 42: 783-793.

Schmierer K. , Scaravilli F. , Altmann DR , Barker GJ , Miller DH Magnetization transfer ratio and myelin in postmortem multiple sclerosis brain. Ann Neurol 2004; 56: 407-415.

Filippi M. , Rocca MA , Martino G. , Horsfield MA , Comi G. Magnetization transfer changes in the normal appearing white matter precede the appearance of enhancing lesions in patients with multiple sclerosis . Ann Neurol 1998; 43: 809-814.

Fazekas F. , Ropele S. , Enzinger C. , Seifert T. , Strasser-Fuchs S. Quantitative magnetization transfer imaging of pre-lesional white-matter changes in multiple sclerosis. Mult Scler 2002; 8: 479-484.

van Waesberghe JH , van Walderveen MA , Castelijns JA , et al. Patterns of lesion development in multiple sclerosis: longitudinal observations with T1-weighted spin-echo and magnetization transfer MR. Am J Neuroradiol 1998; 19: 675-683.

Filippi M. , Rocca MA , Sormani MP , Pereira C. , Comi G. Short-term evolution of individual enhancing MS lesions studied with magnetization transfer imaging. Magn Reson Imaging 1999; 17: 979-984.

Agosta F. , Rovaris M. , Pagani E. , Sormani MP , Comi G. , Filippi M. Magnetization transfer MRI metrics predict the accumulation of disability 8 years later in patients with multiple sclerosis. Brain 2006; 129: 2620-2627.

Kita M. , Goodkin DE , Bacchetti P. , Waubant E. , Nelson SJ , Majumdar S. Magnetization transfer ratio in new MS lesions before and during therapy with IFNbeta-1a. Neurology 2000; 54: 1741-1745.

Richert ND , Ostuni JL , Bash CN , Leist TP , McFarland HF , Frank JA Interferon beta-1b and intravenous methylprednisolone promote lesion recovery in multiple sclerosis. Mult Scler 2001; 7: 49-58.

10.

Polman C. , Barkhof F. , Kappos L. , et al. and the European Oral Interferon Beta-1a in Relapsing-Remitting MS Study Group. (2003). Oral interferon beta-1a in relapsing-remitting multiple sclerosis: a double-blind randomized study. Mult Scler 2003; 9: 342-348.

11.

Snijders TAB. Sampling. In: Leyland AH , Goldstein H (eds) Multilevel modelling of health statistics. New York: Wiley, 2001, p.159-174.

12.

Tofts PS , Steens SC , Cercignani M. , et al. Sources of variation in multi-centre brain MTR histogram studies: body-coil transmission eliminates inter-centre differences. MAGMA 2006; 19: 209-222.

13.

Berry I. , Barker GJ , Barkhof F. , et al. A multicenter measurement of magnetization transfer ratio in normal white matter. J Magn Reson Imaging 1999; 9: 441-446.

14.

Barkhof F. , Bruck W. , De Groot CJA , et al. Remyelinated lesions in multiple sclerosis; magnetic resonance appearance. Arch Neurol 2003; 60: 1073-1081.

15.

Anderson VM , Bartlett JW , Fox NC , Fisniku L. , Miller DH Detecting treatment effects on brain atrophy in relapsing remitting multiple sclerosis: sample size estimates. J Neurol 2007; 254: 1588-1594.

16.

van den Elskamp IJ , Lembcke J. , Dattola V. , et al. Persistent T1 hypointensity as an MRI marker for treatment efficacy in multiple sclerosis . Mult Scler 2008; 14: 764-769.

17.

Minneboo A. , Uitdehaag BM , Ader HJ , Barkhof F. , Polman CH , Castelijns JA Patterns of enhancing lesion evolution in multiple sclerosis are uniform within patients . Neurology 2005; 65: 56-61.

18.

Chen JT , Collins DL , Atkins HL , Freedman MS , Arnold DL Magnetization transfer ratio evolution with demyelination and remyelination in multiple sclerosis lesions. Ann Neurol 2008; 63: 254-262.

19.

Dwyer M. , Bergsland N. , Hussein S. , Durfee J. , Wack D. , Zivadinov R. A sensitive, noise-resistant method for identifying focal demyelination and remyelination in patients with multiple sclerosis via voxel-wise changes in magnetization transfer ratio. J Neurol Sci 2009; 282: 86-95.

20.

Bergerud WA Displaying factor relationships in experiments . Am Stat 1996; 50: 228-233.